Improving Transparency and Accuracy in Medicare Part D Spending Act

Actions

• 2017-03-09Sponsor introductory remarks on measure. (CR E306)
• 2017-02-24Referred to the Subcommittee on Health.
• 2017-02-17Referred to the Subcommittee on Health.
• 2017-02-14Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2017-02-14Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2017-02-14Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2017-02-14Introduced in House
• 2017-02-14Introduced in House

CRS Summary

As of 2017-02-14 (00)

Cosponsors (20)

• Peter Welch (D-VT)
• Doug Collins (R-GA)
• WALTER JONES (R-NC)
• Cathy McMorris Rodgers (R-WA)
• Rod Blum (R-IA)
• Eric Crawford (R-AR)
• Earl Carter (R-GA)
• David Roe (R-TN)
• Brian Babin (R-TX)
• PETE SESSIONS (R-TX)
• Lou Barletta (R-PA)
• Thomas Massie (R-KY)
• Gregg Harper (R-MS)
• A. Ferguson (R-GA)
• ROBERT GOODLATTE (R-VA)
• LLOYD DOGGETT (D-TX)
• Martha Roby (R-AL)
• COLLIN PETERSON (D-MN)
• David Loebsack (D-IA)
• Mark Amodei (R-NV)

Subjects

• Medicare
• Prescription drugs